Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amplia Therapeutics ( (AU:ATX) ) has shared an announcement.
Amplia Therapeutics Limited has announced a Share Purchase Plan (SPP) to raise $2.5 million, with the potential to accept over-subscriptions up to an additional $7.5 million. The SPP, which is not underwritten, is conditional on shareholder approval and is managed by Bell Potter Securities Limited. This move is part of Amplia’s strategic efforts to enhance its financial position and support its ongoing operations, potentially impacting its market standing and offering new opportunities for eligible shareholders and institutional investors.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited operates in the biotechnology industry, focusing on the development of therapeutic solutions. The company is primarily engaged in creating new treatments and therapies, with a market focus on leveraging innovative medical research to address unmet clinical needs.
Average Trading Volume: 7,041,018
Technical Sentiment Signal: Buy
Current Market Cap: A$114.3M
Find detailed analytics on ATX stock on TipRanks’ Stock Analysis page.